Researchers at Thomas Jefferson University Hospital and the Kimmel Cancer Center in Philadelphia, in collaboration with the National Institutes of Health, are initiating a trial to test the effects of high dose vitamin C in patients with non-Hodgkin's lymphoma (NHL). The study will be the first to test the effects of the vitamin when administered intravenously to NHL patients.A team led by Daniel Monti, MD, who is the director of the Myrna Brind Center of Integrative Medicine at Thomas Jefferson, plans to enroll twenty patients for whom standard non-Hodgkin lymphoma therapy has been unsuccessful. Trial participants will receive varying doses of intravenous vitamin C three times per week while being monitored for disease progression. Continue Reading
No comments:
Post a Comment